Businesses for Sale and Investment

Business is involved in the agricultural industry. - We produce medical cannabis. - Business produces this cannabis on their own land. - We own a licence for production. - Business was awarded as the most potent autoflower in the world for 28% THC. - We are the highest CBD and THC, cultivators. - Business has a specific variety with up to 20% CBD with CoA. - Company is ready to start operating but due to a lack of funds for marketing and operation, the owner wants to sell the business. - Business has ample potential and opportunity to make profit. - The selling price includes the stocks that we have. - Business is open to get investors as well. - We have attached our pitch deck which we want to present to our buyers/investors.

European company that grows and sells medical cannabis in Europe and to other countries. - We grow medical cannabis in-house in a controlled environment and distribute them to clients. - Growing 74 varieties of medical cannabis in all ranges of THC and CBD. Good opportunity for CBD products, since Europe considers it as a controlled substance. - We used to grow strawberries before and our products were considered the best strawberries in the world that used to sell at EUR 17 per kg. - We stopped growing strawberries and shifted to medical cannabis due to a family member's health reasons. - Business owner and management members have a strong knowledge of agriculture, medicine, Olímpic Sport level medicine, and pharmaceuticals. - Have a stronger demand than before due to Covid-19. - Have 2 running contracts with medical companies and expect 5-6 new contracts in 1-2 months. - Each contract is valid for 2-3 years and could be renewed. - We currently grow 200-300 kgs of medical cannabis and planning to increase the production due to more demand. - Majority of the clients are from Germany and the Netherlands. - Also working with 20 distributors who are allowed to buy and sell medical cannabis. - Have the best equipment and machinery required for the job and the facility including a cloning room, drying room, security facility, and water tanks.

The company is selling perpetual usage rights of an AI platform that analyzes microbiome and health data to deliver personalized nutrition and wellness plans. - Partners can deploy and white-label the platform locally, offering premium, data-driven health solutions under their own brand. - The sale includes the proprietary core AI algorithms and source code for the microbiome-based precision diet technology. - Partners receive the right to unlimited API access and the ability to customize and train the AI with local data, ensuring relevance and effectiveness in their market. - The license also grants the right to localized deployment on the partner's local servers for compliance and security, and the autonomy to operate and brand the AI as their own. - The capacity of the AI model is virtually unlimited as it is scalable to the partner's server infrastructure, and its condition is excellent, being actively maintained by us. - The tangible assets required for the operation are minimal and fall primarily under the partner's operational responsibility, reflecting a lean, software-driven business model. - The partner is responsible for managing the inventory of sample collection kits (optional cost of GBP 7.5 per kit), requiring only a small fulfillment/warehouse space for storage and shipping. - We have successfully validated our technology on a global scale, processing over 50,000 microbiome samples across 15+ countries and securing strategic partnerships with major industry players. - Our deep-tech innovation has been recognized with prestigious global awards, including the UK Tech Rocketship Award and victories in the Sanofi and Bayer accelerator programs, establishing us as a trusted leader in the personalized health sector. - The business is driven by a seasoned leadership team, including a serial entrepreneur CEO and a CTO with 15+ years of bioinformatics expertise, ensuring clinical validity and robust architecture. - You can establish a high-margin, end-to-end health service by integrating our software with local Next-Generation Sequencing (NGS) laboratories. - In this model, our partner manages the complete value chain: collecting biological samples, processing them locally, and utilizing our AI to generate premium precision diet and health reports. - These complete diagnostic packages are then sold directly to consumers, medical clinics, and hospitals, allowing the partner to capture the full market value of every test performed. - Alternatively, you can leverage your exclusive regional rights to create a scalable B2B sublicensing ecosystem. - Acting as a master distributor, one can sublicense the software access to other local laboratories, wellness apps, and healthcare networks within the territory. - This allows to generate significant recurring revenue by charging own clients for API access or white-labeled portals, effectively monetizing the technology across the entire region without needing to manage every sample personally. - The company is headquartered in London, while the promoter is currently based in the US and has provided that number for all communications.

Deep biotech company incubated by a leading university. - We have developed a portable device with AI-powered image recognition capabilities that can analyze Full Blood Count tests. The device will help with monitoring a patient's health from home for conditions such as leukemia and other types of cancer. - Patient can run the tests from their home and once the sample is analyzed, the results are deployed to our platform (app and browser), which is only shared with the designated doctor. - We also provide sophistical tools that help the patient and doctors to track and monitor health over time. - Have our own production facility with a capacity for 100 devices per month and the development of the device is already complete. We have also applied for a patent in the UK. - Revenue model: We will charge a monthly subscription of GBP 1,000 for medical professionals and doctors, and GBP 100 for patients. - Cost of production of each unit is around GBP 1,200 and we have already targeted the production of 1,000 pieces for the launch. - Well-experienced team of experts and medical consultants with over 30 years of industry experience.

Company and product: Enbiosis has developed an advanced artificial intelligence algorithm that analyzes the human gut microbiome and recommends personalized food and supplements to individuals to improve their gut health and address chronic disorders such as gastrointestinal disorders, skin-related disorders, and weight loss issues. - How it works: Patients/customers send their stool samples to any NGS laboratory in their region. Enbiosis takes the raw bacterial DNA data to the local server (to avoid data protection risks) and creates a personalized report, which is sent to patients and, if required, their practitioners within minutes. - Business model: Enbiosis's microbiome test can be sold through practitioners and/or directly to customers, depending on market dynamics. Practitioners can prescribe the test to patients to generate a personalized diet plan, or patients can follow their personalized nutrition guide through the app to improve general well-being and solve their problems. - Main differentiation: Enbiosis is the only clinically proven precision diet technology that claims to address the main cause of chronic disorders. It has conducted three clinical trials and published the results in peer-reviewed journals. Enbiosis's claims are backed by scientific evidence. - The main reason why investors should consider Enbiosis: In recent years, the number of people seeking to address their health problems through alternative methods instead of pharmaceuticals has been increasing. The challenge in alternative medicine is the lack of scientific data. Enbiosis serves as a bridge between alternative medicine and conventional medicine, and there is significant market potential for Enbiosis. For example, Enbiosis has proven the effectiveness of its technology in patients with IBS, who make up about 10% of the population. Offering individuals the opportunity to solve their chronic problems simply by changing their diet within a specific period is something they are interested in and willing to try. - Additionally, investors/distributors can offer a routine follow-up program to check gut health and prevent any kind of diseases, opening the door to long-term recurring revenue. - We have a trade registration certificate to operate.

Our company is into growing marijuana for medical purposes. - We have an equipped and well-built indoor and outdoor facility that is for the production of dry or wet cannabis flowers. - Currently, we have just done the cultivation for one season which is a process of 6 to 8 months and have a final product stored inside our facility. - The final product is approximately 350 kg, we have not yet sold the products and hence have not reported any revenue. - We have tied-up with a company in Amsterdam that provides us with the seed. - Potential revenue can be generated by selling the final product flower to medical companies, we are not yet tied up with any medical companies. - The business owner is from Albania but due to registration, legal and benefit purposes the business is registered and operating in North Macedonia. - Business does not have any loans and is run by 5 owners. The shareholding pattern is 24:20:20:20.5:15.5. - We have received a valid license from EU regulations for the cultivation and growing of marijuana for medical purposes.